Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

Luisa Giaccone, Andrea Evangelista, Francesca Patriarca, Roberto Sorasio, MD, Massimo Pini, MD, Fabrizio Carnevale Schianca, MD, Moreno Festuccia, Lucia Brunello, Francesco Zallio, MD, Enrico Maffini, Paola Omedè, PhD, Sara Bringhen, MD, Nicola Mordini, MD, Renato Fanin, MD, Massimo Massaia, MD, Antonio Palumbo, MD, Giovannino Ciccone, MDPhD, Mario Boccadoro, MD, Benedetto Bruno, MD PhD

Blood (2016) 128 (22): 3469.

https://doi.org/10.1182/blood.V128.22.3469.3469

Published: 2016

Journal Articles

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Blood (2011) 117 (24): 6721–6727.

https://doi.org/10.1182/blood-2011-03-339945

Published: 2011

Journal Articles

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Blood (2010) 116 (21): 525.

https://doi.org/10.1182/blood.V116.21.525.525

Published: 2010

Journal Articles

Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.

Luisa Giaccone, Moreno Festuccia, Roberto Sorasio, Nicola Mordini, Fabrizio Carnevale Schianca, Francesca Patriarca, Marco Casini, Anna Paola Iori, Robin Foà, Mario Boccadoro, Benedetto Bruno

Blood (2009) 114 (22): 4330.

https://doi.org/10.1182/blood.V114.22.4330.4330

Published: 2009

Journal Articles

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Blood (2009) 113 (14): 3375–3382.

https://doi.org/10.1182/blood-2008-07-167379

Published: 2009

Journal Articles

Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers

Dario Sangiolo, MD, Noela Jordaney, Giulia Mesiano, Paola Circosta, Angela Elia, Stefania Stella, Maja Todorovic, Fabrizio Carnevale-Schianca, Massimo Aglietta, Alessandro Cignetti

Blood (2008) 112 (11): 3515.

https://doi.org/10.1182/blood.V112.11.3515.3515

Published: 2008

Journal Articles

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD

Blood (2006) 107 (9): 3795–3803.

https://doi.org/10.1182/blood-2005-10-3945

Published: 2006

Journal Articles

Expanded Human NKT Type II Cells: Effective Against Colon Cancer Cells, Safe across Major MHC Barriers and Successfully Expandable after Non-Myeloablative HCT for Solid Tumors.

Dario Sangiolo, MD, Emanuela Martinuzzi, Fabrizio Carnevale-Schianca, MD, Antonio Capaldi, MD, Massimo Geuna, PhD, Katiuscia Vitaggio, Massimo Aglietta, MD, Alessandro Cignetti, MD, PhD

Blood (2005) 106 (11): 5239.

https://doi.org/10.1182/blood.V106.11.5239.5239

Published: 2005

Journal Articles

Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant.

Luisa Giaccone, MD, Marcello Rotta, MD, Bernardino Allione, MD, Fabrizio Carnevale-Schianca, MD, Carlo Rosanelli, MD, Giovannino Ciccone, MD, Marco Casini, MD, Antonio Capaldi, MD, Gabriele Aitoro, MD, Paola Omedè, PhD, Silvano Battaglio, PhD, Massimo Massaia, MD, Paolo Coser, MD, Massimo Aglietta, MD, Alessandro Levis, MD, Rainer Storb, MD, Benedetto Bruno, MD, PhD, Mario Boccadoro, MD

Blood (2004) 104 (11): 2310.

https://doi.org/10.1182/blood.V104.11.2310.2310

Published: 2004

NARROW

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD

Expanded Human NKT Type II Cells: Effective Against Colon Cancer Cells, Safe across Major MHC Barriers and Successfully Expandable after Non-Myeloablative HCT for Solid Tumors.

Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only